Mineralocorticoid receptor antagonists reduce risk of cardiovascular events in patients with heart failure Post author: Post published:September 3, 2024 Post category:uncategorized MRAs significantly lower the risk of cardiovascular death and HF hospitalization in heart failure patients. You Might Also Like Breakthrough in blood stem cell development offers hope for leukemia and bone marrow failure September 2, 2024 Long-term study reveals safety of metformin use during pregnancy June 3, 2024 Diabetes management program cuts dementia risk in type 2 patients February 13, 2024
Breakthrough in blood stem cell development offers hope for leukemia and bone marrow failure September 2, 2024